ReP USP - Resultado da busca

Trabalho de evento-resumo periodico
Molecular analysis of RAS genes mutations in patients with cervical adenocarcinoma (2015)
Garces, Alvaro Henrique Ingles; Inada, Haynna Kimie Pimenta; Mora, Paulo; Torres, Michelle; Almeida, Fabio Marques de; Longatto-Filho, Adhemar; Villa, Luisa Lina; Moreira, Marise Amaral Reboucas; Ferreira, Carlos G. M.; De Melo, Andreia Cristina
Source: Journal of Clinical Oncology. Conference titles: ASCO Annual Meeting. Unidade: FM
Subjects: BRASILEIROS, MUTAÇÃO, ADENOCARCINOMAS, ESTUDOS DE COORTES, CARCINOMA DE CÉLULAS ESCAMOSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GARCES, Alvaro Henrique Ingles et al. Molecular analysis of RAS genes mutations in patients with cervical adenocarcinoma. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e22222?sid=374d0eb4-1f7b-494e-8f0f-89a24d481b1c. Acesso em: 23 maio 2024. , 2015
APA
Garces, A. H. I., Inada, H. K. P., Mora, P., Torres, M., Almeida, F. M. de, Longatto-Filho, A., et al. (2015). Molecular analysis of RAS genes mutations in patients with cervical adenocarcinoma. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e22222?sid=374d0eb4-1f7b-494e-8f0f-89a24d481b1c
NLM
Garces AHI, Inada HKP, Mora P, Torres M, Almeida FM de, Longatto-Filho A, Villa LL, Moreira MAR, Ferreira CGM, De Melo AC. Molecular analysis of RAS genes mutations in patients with cervical adenocarcinoma [Internet]. Journal of Clinical Oncology. 2015 ; 33( 15S ):[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e22222?sid=374d0eb4-1f7b-494e-8f0f-89a24d481b1c
Vancouver
Garces AHI, Inada HKP, Mora P, Torres M, Almeida FM de, Longatto-Filho A, Villa LL, Moreira MAR, Ferreira CGM, De Melo AC. Molecular analysis of RAS genes mutations in patients with cervical adenocarcinoma [Internet]. Journal of Clinical Oncology. 2015 ; 33( 15S ):[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e22222?sid=374d0eb4-1f7b-494e-8f0f-89a24d481b1c
Trabalho de evento-resumo periodico
Somatic mutations in Luminal HER2 negative tumors from young breast cancer patients (2015)
Encinas, Giselly; Estevez-Diz, Maria Del Pilar; Lyra, Eduardo C.; Katayama, Maria Lucia Hirata; Pasini, Fatima Solange; Maistro, Simone; Sabelnykova, Veronica; Boutros, Paul; Brentani, Maria Mitzi; Basso, Ricardo; De Gouvea, Ana Carolina Ribeiro Chaves; Chammas, Roger; Goes, Joao Carlos Guedes Sampaio; Folgueira, Maria A. A. Koike
Source: Journal of Clinical Oncology. Conference titles: ASCO Annual Meeting. Unidade: FM
Subjects: NEOPLASIAS MAMÁRIAS, MUTAÇÃO GENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ENCINAS, Giselly et al. Somatic mutations in Luminal HER2 negative tumors from young breast cancer patients. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1544?sid=ef1e190f-d5ee-4417-942f-c3e8a7c0c046. Acesso em: 23 maio 2024. , 2015
APA
Encinas, G., Estevez-Diz, M. D. P., Lyra, E. C., Katayama, M. L. H., Pasini, F. S., Maistro, S., et al. (2015). Somatic mutations in Luminal HER2 negative tumors from young breast cancer patients. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1544?sid=ef1e190f-d5ee-4417-942f-c3e8a7c0c046
NLM
Encinas G, Estevez-Diz MDP, Lyra EC, Katayama MLH, Pasini FS, Maistro S, Sabelnykova V, Boutros P, Brentani MM, Basso R, De Gouvea ACRC, Chammas R, Goes JCGS, Folgueira MAAK. Somatic mutations in Luminal HER2 negative tumors from young breast cancer patients [Internet]. Journal of Clinical Oncology. 2015 ; 33( 15S ):[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1544?sid=ef1e190f-d5ee-4417-942f-c3e8a7c0c046
Vancouver
Encinas G, Estevez-Diz MDP, Lyra EC, Katayama MLH, Pasini FS, Maistro S, Sabelnykova V, Boutros P, Brentani MM, Basso R, De Gouvea ACRC, Chammas R, Goes JCGS, Folgueira MAAK. Somatic mutations in Luminal HER2 negative tumors from young breast cancer patients [Internet]. Journal of Clinical Oncology. 2015 ; 33( 15S ):[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1544?sid=ef1e190f-d5ee-4417-942f-c3e8a7c0c046
Trabalho de evento-resumo periodico
Evaluation of predictive biomarkers of response and prognosis in patients with high-grade extrapulmonary neuroendocrine carcinomas treated with platin-based chemotherapy (2015)
Rego, Juliana Florinda De Mendonga; Medeiros, Raphael Salles S.; Braghiroli, Maria Ignez Freitas Melro; Galvao, Breno; Bezerra Neto, Joao Evangelista; Munhoz, Rodrigo Ramella; Guerra, Juliana Mariotti; Kimura, Lidia; Nonogaki, Suely; Pfiffer, Tulio Eduardo Flesch; Hoff, Paulo Marcelo; Rocha Filho, Duilio; Costa, Frederico; Riechelmann, Rachel Pimenta
Source: Journal of Clinical Oncology. Conference titles: ASCO Annual Meeting. Unidade: FM
Subjects: PROGNÓSTICO, BIOMARCADORES, CARCINOMA NEUROENDÓCRINO (QUIMIOTERAPIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
REGO, Juliana Florinda De Mendonga et al. Evaluation of predictive biomarkers of response and prognosis in patients with high-grade extrapulmonary neuroendocrine carcinomas treated with platin-based chemotherapy. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15183?sid=3a7d1fff-5c77-4444-a533-5a64108ca202. Acesso em: 23 maio 2024. , 2015
APA
Rego, J. F. D. M., Medeiros, R. S. S., Braghiroli, M. I. F. M., Galvao, B., Bezerra Neto, J. E., Munhoz, R. R., et al. (2015). Evaluation of predictive biomarkers of response and prognosis in patients with high-grade extrapulmonary neuroendocrine carcinomas treated with platin-based chemotherapy. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15183?sid=3a7d1fff-5c77-4444-a533-5a64108ca202
NLM
Rego JFDM, Medeiros RSS, Braghiroli MIFM, Galvao B, Bezerra Neto JE, Munhoz RR, Guerra JM, Kimura L, Nonogaki S, Pfiffer TEF, Hoff PM, Rocha Filho D, Costa F, Riechelmann RP. Evaluation of predictive biomarkers of response and prognosis in patients with high-grade extrapulmonary neuroendocrine carcinomas treated with platin-based chemotherapy [Internet]. Journal of Clinical Oncology. 2015 ; 33( 15S ):[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15183?sid=3a7d1fff-5c77-4444-a533-5a64108ca202
Vancouver
Rego JFDM, Medeiros RSS, Braghiroli MIFM, Galvao B, Bezerra Neto JE, Munhoz RR, Guerra JM, Kimura L, Nonogaki S, Pfiffer TEF, Hoff PM, Rocha Filho D, Costa F, Riechelmann RP. Evaluation of predictive biomarkers of response and prognosis in patients with high-grade extrapulmonary neuroendocrine carcinomas treated with platin-based chemotherapy [Internet]. Journal of Clinical Oncology. 2015 ; 33( 15S ):[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15183?sid=3a7d1fff-5c77-4444-a533-5a64108ca202
Artigo de periodico
Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial (2014)
Hoff, Paulo M.; Saragiotto, Daniel F.; Barrios, Carlos H.; Giglio, Auro del; Coutinho, Anelisa K.; Andrade, Aline C.; Dutra, Carolina; Forones, Nora M.; Correa, Mariangela; Portella, Maria do Socorro O.; Passos, Vanessa Q.; Chinen, Renata N.; Eyll, Brigitte van
Source: Journal of Clinical Oncology. Unidade: FM
Subjects: QUIMIOTERAPIA, NEOPLASIAS COLORRETAIS (COMPLICAÇÕES), DIARREIA (TERAPIA), ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HOFF, Paulo M. et al. Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial. Journal of Clinical Oncology, v. 32, n. 10, p. 1006-1011, 2014Tradução . . Disponível em: https://doi.org/10.1200/JCO.2013.50.8077. Acesso em: 23 maio 2024.
APA
Hoff, P. M., Saragiotto, D. F., Barrios, C. H., Giglio, A. del, Coutinho, A. K., Andrade, A. C., et al. (2014). Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial. Journal of Clinical Oncology, 32( 10), 1006-1011. doi:10.1200/JCO.2013.50.8077
NLM
Hoff PM, Saragiotto DF, Barrios CH, Giglio A del, Coutinho AK, Andrade AC, Dutra C, Forones NM, Correa M, Portella M do SO, Passos VQ, Chinen RN, Eyll B van. Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial [Internet]. Journal of Clinical Oncology. 2014 ; 32( 10): 1006-1011.[citado 2024 maio 23 ] Available from: https://doi.org/10.1200/JCO.2013.50.8077
Vancouver
Hoff PM, Saragiotto DF, Barrios CH, Giglio A del, Coutinho AK, Andrade AC, Dutra C, Forones NM, Correa M, Portella M do SO, Passos VQ, Chinen RN, Eyll B van. Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial [Internet]. Journal of Clinical Oncology. 2014 ; 32( 10): 1006-1011.[citado 2024 maio 23 ] Available from: https://doi.org/10.1200/JCO.2013.50.8077
Artigo de periodico
Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study (2014)
Salar, Antonio; Avivi, Irit; Bittner, Beate; Bouabdallah, Reda; Brewster, Mike; Catalani, Olivier; Follows, George; Haynes, Andrew; Hourcade-Potelleret, Florence; Janikova, Andrea; Larouche, Jean-François; McIntyre, Christine; Pedersen, Michael; Pereira, Juliana; Sayyed, Pakeeza
Source: Journal of Clinical Oncology. Unidade: FM
Subjects: LINFOMA (TERAPIA), MEDICAÇÃO INTRAVENOSA, ANTINEOPLÁSICOS (ADMINISTRAÇÃO E DOSAGEM)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SALAR, Antonio et al. Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study. Journal of Clinical Oncology, v. 32, n. 17, p. 1782-1791, 2014Tradução . . Disponível em: https://doi.org/10.1200/JCO.2013.52.2631. Acesso em: 23 maio 2024.
APA
Salar, A., Avivi, I., Bittner, B., Bouabdallah, R., Brewster, M., Catalani, O., et al. (2014). Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study. Journal of Clinical Oncology, 32( 17), 1782-1791. doi:10.1200/JCO.2013.52.2631
NLM
Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, Larouche J-F, McIntyre C, Pedersen M, Pereira J, Sayyed P. Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study [Internet]. Journal of Clinical Oncology. 2014 ; 32( 17): 1782-1791.[citado 2024 maio 23 ] Available from: https://doi.org/10.1200/JCO.2013.52.2631
Vancouver
Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, Larouche J-F, McIntyre C, Pedersen M, Pereira J, Sayyed P. Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study [Internet]. Journal of Clinical Oncology. 2014 ; 32( 17): 1782-1791.[citado 2024 maio 23 ] Available from: https://doi.org/10.1200/JCO.2013.52.2631
Artigo de periodico
Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II) (2012)
Hoff, Paulo M.; Hochhaus, Andreas; Pestalozzi, Bernhard C.; Tebbutt, Niall C.; Li, Jin; Kim, Tae Won; Koynov, Krassimir D.; Kurteva, Galina; Pintér, Tamás; Cheng, Ying; Eyll, Brigitte van; Pike, Laura; Fielding, Anitra; Robertson, Jane D.; Saunders, Mark P.
Source: Journal of Clinical Oncology. Unidade: FM
Subjects: PLACEBOS (ADMINISTRAÇÃO), ANTINEOPLÁSICOS (APLICAÇÕES TERAPÊUTICAS), MÉTODO DUPLO-CEGO, METÁSTASE NEOPLÁSICA, NEOPLASIAS COLORRETAIS (SECUNDÁRIO;TERAPIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HOFF, Paulo M. et al. Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology, v. 30, n. 29, p. 3596-3603, 2012Tradução . . Disponível em: https://doi.org/10.1200/JCO.2012.42.6031. Acesso em: 23 maio 2024.
APA
Hoff, P. M., Hochhaus, A., Pestalozzi, B. C., Tebbutt, N. C., Li, J., Kim, T. W., et al. (2012). Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology, 30( 29), 3596-3603. doi:10.1200/JCO.2012.42.6031
NLM
Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, Eyll B van, Pike L, Fielding A, Robertson JD, Saunders MP. Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II) [Internet]. Journal of Clinical Oncology. 2012 ; 30( 29): 3596-3603.[citado 2024 maio 23 ] Available from: https://doi.org/10.1200/JCO.2012.42.6031
Vancouver
Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, Eyll B van, Pike L, Fielding A, Robertson JD, Saunders MP. Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II) [Internet]. Journal of Clinical Oncology. 2012 ; 30( 29): 3596-3603.[citado 2024 maio 23 ] Available from: https://doi.org/10.1200/JCO.2012.42.6031
Artigo de periodico
Giant-Cell Tumor of the Tendon Sheath in the Upper Cervical Spine (2012)
Teixeira, William Gemio Jacobsen; Lara Jr., Nilton Alves; Narazaki, Douglas Kenji; Oliveira, Claudia de; Cavalcanti, Conrado; Marins, Lidiane Vieira; Cristante, Alexandre Fogaça; Teixeira, Manoel Jacobsen; Barros Filho, Tarcísio Eloy de
Source: Journal of Clinical Oncology. Unidade: FM
Subjects: TOMOGRAFIA COMPUTADORIZADA POR RAIOS X, DIAGNÓSTICO POR IMAGEM, IMAGEM POR RESSONÂNCIA MEGNÉTICA, REGIÃO CERVICAL (PATOLOGIA), BIÓPSIA, NEOPLASIAS DE CABEÇA E PESCOÇO (DIAGNÓSTICO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TEIXEIRA, William Gemio Jacobsen et al. Giant-Cell Tumor of the Tendon Sheath in the Upper Cervical Spine. Journal of Clinical Oncology, v. 30, n. 26, p. e250-e253, 2012Tradução . . Disponível em: https://doi.org/10.1200/JCO.2011.36.7482. Acesso em: 23 maio 2024.
APA
Teixeira, W. G. J., Lara Jr., N. A., Narazaki, D. K., Oliveira, C. de, Cavalcanti, C., Marins, L. V., et al. (2012). Giant-Cell Tumor of the Tendon Sheath in the Upper Cervical Spine. Journal of Clinical Oncology, 30( 26), e250-e253. doi:10.1200/JCO.2011.36.7482
NLM
Teixeira WGJ, Lara Jr. NA, Narazaki DK, Oliveira C de, Cavalcanti C, Marins LV, Cristante AF, Teixeira MJ, Barros Filho TE de. Giant-Cell Tumor of the Tendon Sheath in the Upper Cervical Spine [Internet]. Journal of Clinical Oncology. 2012 ; 30( 26): e250-e253.[citado 2024 maio 23 ] Available from: https://doi.org/10.1200/JCO.2011.36.7482
Vancouver
Teixeira WGJ, Lara Jr. NA, Narazaki DK, Oliveira C de, Cavalcanti C, Marins LV, Cristante AF, Teixeira MJ, Barros Filho TE de. Giant-Cell Tumor of the Tendon Sheath in the Upper Cervical Spine [Internet]. Journal of Clinical Oncology. 2012 ; 30( 26): e250-e253.[citado 2024 maio 23 ] Available from: https://doi.org/10.1200/JCO.2011.36.7482
Artigo de periodico
Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome (2011)
Begnami, Maria D; Fukuda, Emy; Fregnani, José H. T. G; Nonogaki, Suely; Montagnini, André L; Costa Júnior, Wilson L. da; Soares, Fernando Augusto
Source: Journal of Clinical Oncology. Unidade: FO
Subjects: CARCINOMA, TRATO DIGESTIVO DE ANIMAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BEGNAMI, Maria D et al. Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome. Journal of Clinical Oncology, v. 29, n. 22, p. 3030-3036, 2011Tradução . . Disponível em: https://doi.org/10.1200/jco.2010.33.6313. Acesso em: 23 maio 2024.
APA
Begnami, M. D., Fukuda, E., Fregnani, J. H. T. G., Nonogaki, S., Montagnini, A. L., Costa Júnior, W. L. da, & Soares, F. A. (2011). Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome. Journal of Clinical Oncology, 29( 22), 3030-3036. doi:10.1200/jco.2010.33.6313
NLM
Begnami MD, Fukuda E, Fregnani JHTG, Nonogaki S, Montagnini AL, Costa Júnior WL da, Soares FA. Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome [Internet]. Journal of Clinical Oncology. 2011 ; 29( 22): 3030-3036.[citado 2024 maio 23 ] Available from: https://doi.org/10.1200/jco.2010.33.6313
Vancouver
Begnami MD, Fukuda E, Fregnani JHTG, Nonogaki S, Montagnini AL, Costa Júnior WL da, Soares FA. Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome [Internet]. Journal of Clinical Oncology. 2011 ; 29( 22): 3030-3036.[citado 2024 maio 23 ] Available from: https://doi.org/10.1200/jco.2010.33.6313
Artigo de periodico
Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group-Protocol ALL-99 (2010)
Brandalise, Silvia R.; Pinheiro, Vitória R.; Aguiar, Simone S.; Matsuda, Eduardo I.; Otubo, Rosemary; Yunes, José A.; Pereira, Waldir A.; Carvalho, Eny G.; Cristofani, Lilian M.; Souza, Marcelo S.; Lee, Maria L.; Dobbin, Jane A.; Pombo-de-Oliveira, Maria S.; Lopes, Luiz F.; Melnikoff, Katharina N. T.; Brunetto, Algemir L.; Tone, Luiz Gonzaga; Scrideli, Carlos Alberto; Morais, Vera L. L.; Viana, Marcos B.
Source: Journal of Clinical Oncology. Unidade: FMRP
Subjects: CRIANÇAS, LEUCEMIA (TRATAMENTO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRANDALISE, Silvia R. et al. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group-Protocol ALL-99. Journal of Clinical Oncology, v. 28, n. 11, p. 1911-1918, 2010Tradução . . Acesso em: 23 maio 2024.
APA
Brandalise, S. R., Pinheiro, V. R., Aguiar, S. S., Matsuda, E. I., Otubo, R., Yunes, J. A., et al. (2010). Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group-Protocol ALL-99. Journal of Clinical Oncology, 28( 11), 1911-1918.
NLM
Brandalise SR, Pinheiro VR, Aguiar SS, Matsuda EI, Otubo R, Yunes JA, Pereira WA, Carvalho EG, Cristofani LM, Souza MS, Lee ML, Dobbin JA, Pombo-de-Oliveira MS, Lopes LF, Melnikoff KNT, Brunetto AL, Tone LG, Scrideli CA, Morais VLL, Viana MB. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group-Protocol ALL-99. Journal of Clinical Oncology. 2010 ; 28( 11): 1911-1918.[citado 2024 maio 23 ]
Vancouver
Brandalise SR, Pinheiro VR, Aguiar SS, Matsuda EI, Otubo R, Yunes JA, Pereira WA, Carvalho EG, Cristofani LM, Souza MS, Lee ML, Dobbin JA, Pombo-de-Oliveira MS, Lopes LF, Melnikoff KNT, Brunetto AL, Tone LG, Scrideli CA, Morais VLL, Viana MB. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group-Protocol ALL-99. Journal of Clinical Oncology. 2010 ; 28( 11): 1911-1918.[citado 2024 maio 23 ]
Trabalho de evento-resumo periodico
Breast cancer gene expression profile in young women who are noncarriers of BRCA1/2 mutations with and without familial history (2010)
Carraro, D. M.; Moreira-Filho, C. A.; Ramos, P. L.; Lisboa, B. C.; Brentani, H.; Achatz, M. W.; Folgueira, M. A. Koike; Katayama, M. H.; Brentani , M.
Source: Journal of Clinical Oncology. Conference titles: Annual Meeting of the American Society of Clinical Oncology. Unidade: FM
Subjects: ESTUDOS RETROSPECTIVOS, NEOPLASIAS MÁMARIAS (GENÉTICA), DOENÇAS HEREDITÁRIAS, EXPRESSÃO GÊNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARRARO, D. M. et al. Breast cancer gene expression profile in young women who are noncarriers of BRCA1/2 mutations with and without familial history. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1538. Acesso em: 23 maio 2024. , 2010
APA
Carraro, D. M., Moreira-Filho, C. A., Ramos, P. L., Lisboa, B. C., Brentani, H., Achatz, M. W., et al. (2010). Breast cancer gene expression profile in young women who are noncarriers of BRCA1/2 mutations with and without familial history. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1538
NLM
Carraro DM, Moreira-Filho CA, Ramos PL, Lisboa BC, Brentani H, Achatz MW, Folgueira MAK, Katayama MH, Brentani M. Breast cancer gene expression profile in young women who are noncarriers of BRCA1/2 mutations with and without familial history [Internet]. Journal of Clinical Oncology. 2010 ; 28( 15S ): 162s.[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1538
Vancouver
Carraro DM, Moreira-Filho CA, Ramos PL, Lisboa BC, Brentani H, Achatz MW, Folgueira MAK, Katayama MH, Brentani M. Breast cancer gene expression profile in young women who are noncarriers of BRCA1/2 mutations with and without familial history [Internet]. Journal of Clinical Oncology. 2010 ; 28( 15S ): 162s.[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1538
Trabalho de evento-resumo periodico
Publication bias in randomized controlled trials (RCTs) of colorectal cancer presented at ASCO Annual Meetings (2010)
Leal, A. I.; Barra, W. F.; Saragiotto, D. F.; Saad, E. D.; Hoff, P. M.
Source: Journal of Clinical Oncology. Conference titles: Annual Meeting of the American Society of Clinical Oncology. Unidade: FM
Subjects: NEOPLASIAS COLORRETAIS, ESTUDO DE CASO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LEAL, A. I. et al. Publication bias in randomized controlled trials (RCTs) of colorectal cancer presented at ASCO Annual Meetings. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/6116. Acesso em: 23 maio 2024. , 2010
APA
Leal, A. I., Barra, W. F., Saragiotto, D. F., Saad, E. D., & Hoff, P. M. (2010). Publication bias in randomized controlled trials (RCTs) of colorectal cancer presented at ASCO Annual Meetings. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/6116
NLM
Leal AI, Barra WF, Saragiotto DF, Saad ED, Hoff PM. Publication bias in randomized controlled trials (RCTs) of colorectal cancer presented at ASCO Annual Meetings [Internet]. Journal of Clinical Oncology. 2010 ; 28( 15S ): 476s.[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/6116
Vancouver
Leal AI, Barra WF, Saragiotto DF, Saad ED, Hoff PM. Publication bias in randomized controlled trials (RCTs) of colorectal cancer presented at ASCO Annual Meetings [Internet]. Journal of Clinical Oncology. 2010 ; 28( 15S ): 476s.[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/6116
Artigo de periodico
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance (2010)
Kopetz, Scott; Hoff, Paulo M.; Morris, Jeffrey S.; Wolff, Robert A.; Eng, Cathy; Glover, Katrina Y.; Adinin, Rosie; Overman, Michael J.; Valero, Vincete; Wen, Sijin; Lieu, Christopher; Yan, Shaoyu; Tran, Hai T.; Ellis, Lee M.; Abbruzzese, James L.; Heymach, John V.
Source: Journal of Clinical Oncology. Unidade: FM
Subjects: NEOPLASIAS COLORRETAIS, ANTINEOPLÁSICOS (USO TERAPÊUTICO), BIOMARCADORES, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KOPETZ, Scott et al. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. Journal of Clinical Oncology, v. 28, n. 3, p. 453-459, 2010Tradução . . Disponível em: https://doi.org/10.1200/JCO.2009.24.8252. Acesso em: 23 maio 2024.
APA
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., et al. (2010). Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. Journal of Clinical Oncology, 28( 3), 453-459. doi:10.1200/JCO.2009.24.8252
NLM
Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance [Internet]. Journal of Clinical Oncology. 2010 ; 28( 3): 453-459.[citado 2024 maio 23 ] Available from: https://doi.org/10.1200/JCO.2009.24.8252
Vancouver
Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance [Internet]. Journal of Clinical Oncology. 2010 ; 28( 3): 453-459.[citado 2024 maio 23 ] Available from: https://doi.org/10.1200/JCO.2009.24.8252
Trabalho de evento-resumo periodico
ERCC1 protein, mRNA expression, and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma (HNSCC) patients treated with surgery and adjuvant cisplatin-based chemoradiation (CRT) (2010)
Castro, G.; Pasini, F. S.; Siqueira, S. A.; Ferraz, A. R.; Villar, R. C.; Snitcovsky, I. M.; Federico, M. H.
Source: Journal of Clinical Oncology. Conference titles: Annual Meeting of the American Society of Clinical Oncology. Unidade: FM
Subjects: POLIMORFISMO, NEOPLASIAS DE CABEÇA E PESCOÇO, QUIMIOTERÁPICOS, PESCOÇO (GENÉTICA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CASTRO, G. et al. ERCC1 protein, mRNA expression, and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma (HNSCC) patients treated with surgery and adjuvant cisplatin-based chemoradiation (CRT). Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5540. Acesso em: 23 maio 2024. , 2010
APA
Castro, G., Pasini, F. S., Siqueira, S. A., Ferraz, A. R., Villar, R. C., Snitcovsky, I. M., & Federico, M. H. (2010). ERCC1 protein, mRNA expression, and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma (HNSCC) patients treated with surgery and adjuvant cisplatin-based chemoradiation (CRT). Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5540
NLM
Castro G, Pasini FS, Siqueira SA, Ferraz AR, Villar RC, Snitcovsky IM, Federico MH. ERCC1 protein, mRNA expression, and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma (HNSCC) patients treated with surgery and adjuvant cisplatin-based chemoradiation (CRT) [Internet]. Journal of Clinical Oncology. 2010 ; 28( 15S ): 431s.[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5540
Vancouver
Castro G, Pasini FS, Siqueira SA, Ferraz AR, Villar RC, Snitcovsky IM, Federico MH. ERCC1 protein, mRNA expression, and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma (HNSCC) patients treated with surgery and adjuvant cisplatin-based chemoradiation (CRT) [Internet]. Journal of Clinical Oncology. 2010 ; 28( 15S ): 431s.[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5540
Trabalho de evento-resumo periodico
Evaluation of recombinant bacillus Calmette-Guerin expressing pertussis toxin in bladder cancer (2009)
Chade, D. C.; Borra, R.; Leite, K. R.; Villanova, F. E.; Nascimento, I.; Liete, L. C.; Srougi, M.; Andrade, P. M.
Source: Journal of Clinical Oncology. Conference titles: Annual Meeting of the American Society of Clinical Oncology. Unidade: FM
Subjects: NEOPLASIAS DA BEXIGA, TOXICINAS (PATOGENICIDADE), MODELOS ANIMAIS, BIOLOGIA MOLECULAR, RESUMOS (EVENTOS), PROGNÓSTICO, CAMUNDONGOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHADE, D. C. et al. Evaluation of recombinant bacillus Calmette-Guerin expressing pertussis toxin in bladder cancer. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/3064?sid=fd23f8bf-7b03-4ee1-ac61-71d5e7687748. Acesso em: 23 maio 2024. , 2009
APA
Chade, D. C., Borra, R., Leite, K. R., Villanova, F. E., Nascimento, I., Liete, L. C., et al. (2009). Evaluation of recombinant bacillus Calmette-Guerin expressing pertussis toxin in bladder cancer. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/27/15S/3064?sid=fd23f8bf-7b03-4ee1-ac61-71d5e7687748
NLM
Chade DC, Borra R, Leite KR, Villanova FE, Nascimento I, Liete LC, Srougi M, Andrade PM. Evaluation of recombinant bacillus Calmette-Guerin expressing pertussis toxin in bladder cancer [Internet]. Journal of Clinical Oncology. 2009 ; 27( 15S ): 145s.[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/3064?sid=fd23f8bf-7b03-4ee1-ac61-71d5e7687748
Vancouver
Chade DC, Borra R, Leite KR, Villanova FE, Nascimento I, Liete LC, Srougi M, Andrade PM. Evaluation of recombinant bacillus Calmette-Guerin expressing pertussis toxin in bladder cancer [Internet]. Journal of Clinical Oncology. 2009 ; 27( 15S ): 145s.[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/3064?sid=fd23f8bf-7b03-4ee1-ac61-71d5e7687748
Trabalho de evento-resumo periodico
Fifteen years experience of the Brazilian Osteosarcoma Treatment Group (BOTG) (2009)
Petrilli, A.S.; Camargo, B. de; Odone Filho, V.; Lustosa, D.; Borsato, M. L.; Calheiros, L. M.; Brunetto, A. L.; Barreto, J. H.; Ferraro, A. A.
Source: Journal of Clinical Oncology. Conference titles: Annual Meeting of the American Society of Clinical Oncology. Unidade: FM
Subjects: OSTEOSSARCOMA (TERAPIA), SEGUIMENTOS, METÁSTASE NEOPLÁSICA, RESUMOS (EVENTOS), BRASIL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PETRILLI, A.S. et al. Fifteen years experience of the Brazilian Osteosarcoma Treatment Group (BOTG). Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10039?sid=ed0a34dd-832c-4fbd-b8bf-4d96e7d74ccc. Acesso em: 23 maio 2024. , 2009
APA
Petrilli, A. S., Camargo, B. de, Odone Filho, V., Lustosa, D., Borsato, M. L., Calheiros, L. M., et al. (2009). Fifteen years experience of the Brazilian Osteosarcoma Treatment Group (BOTG). Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10039?sid=ed0a34dd-832c-4fbd-b8bf-4d96e7d74ccc
NLM
Petrilli AS, Camargo B de, Odone Filho V, Lustosa D, Borsato ML, Calheiros LM, Brunetto AL, Barreto JH, Ferraro AA. Fifteen years experience of the Brazilian Osteosarcoma Treatment Group (BOTG) [Internet]. Journal of Clinical Oncology. 2009 ; 27( 15S ): 529s.[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10039?sid=ed0a34dd-832c-4fbd-b8bf-4d96e7d74ccc
Vancouver
Petrilli AS, Camargo B de, Odone Filho V, Lustosa D, Borsato ML, Calheiros LM, Brunetto AL, Barreto JH, Ferraro AA. Fifteen years experience of the Brazilian Osteosarcoma Treatment Group (BOTG) [Internet]. Journal of Clinical Oncology. 2009 ; 27( 15S ): 529s.[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10039?sid=ed0a34dd-832c-4fbd-b8bf-4d96e7d74ccc
Trabalho de evento-resumo periodico
Oral mucositis prevention by low-level laser therapy in head and neck cancer patients submitted to concurrent chemoradiation: A prospective randomized study (2009)
Castro Jr., G.; Lima, A. G. de; Lopes, D. R.; Ortegosa, M. V.; Rosalmeida, M. C.; Gil, E.; Cavalcanti Leal, A. I.; Federico, M. H.; Villar, R. C.; Snitcovsky, I.
Source: Journal of Clinical Oncology. Conference titles: Annual Meeting of the American Society of Clinical Oncology. Unidade: FM
Subjects: NEOPLASIAS DE CABEÇA E PESCOÇO (QUIMIOTERAPIA), ESTUDOS RETROSPECTIVOS, METÁSTASE NEOPLÁSICA, MUCOSA ORAL (FISIOPATOLOGIA), RESUMOS (EVENTOS)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CASTRO JR., G. et al. Oral mucositis prevention by low-level laser therapy in head and neck cancer patients submitted to concurrent chemoradiation: A prospective randomized study. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6019?sid=0a9bbbd9-2e8c-40da-9902-61e6dd6449b8. Acesso em: 23 maio 2024. , 2009
APA
Castro Jr., G., Lima, A. G. de, Lopes, D. R., Ortegosa, M. V., Rosalmeida, M. C., Gil, E., et al. (2009). Oral mucositis prevention by low-level laser therapy in head and neck cancer patients submitted to concurrent chemoradiation: A prospective randomized study. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6019?sid=0a9bbbd9-2e8c-40da-9902-61e6dd6449b8
NLM
Castro Jr. G, Lima AG de, Lopes DR, Ortegosa MV, Rosalmeida MC, Gil E, Cavalcanti Leal AI, Federico MH, Villar RC, Snitcovsky I. Oral mucositis prevention by low-level laser therapy in head and neck cancer patients submitted to concurrent chemoradiation: A prospective randomized study [Internet]. Journal of Clinical Oncology. 2009 ; 27( 15S ): 305s.[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6019?sid=0a9bbbd9-2e8c-40da-9902-61e6dd6449b8
Vancouver
Castro Jr. G, Lima AG de, Lopes DR, Ortegosa MV, Rosalmeida MC, Gil E, Cavalcanti Leal AI, Federico MH, Villar RC, Snitcovsky I. Oral mucositis prevention by low-level laser therapy in head and neck cancer patients submitted to concurrent chemoradiation: A prospective randomized study [Internet]. Journal of Clinical Oncology. 2009 ; 27( 15S ): 305s.[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6019?sid=0a9bbbd9-2e8c-40da-9902-61e6dd6449b8
Trabalho de evento-resumo periodico
Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemothrapy (2009)
Graziani, Silvia Regina; Mendes, Sergio; Vitório, Tatiana Solano; Padoveze, Amanda Felippe; Hegg, Roberto; Bydlowski, Sérgio Paulo; Maranhão, Raul Cavalcante
Source: Journal of Clinical Oncology. Conference titles: Annual Scientific Meeting of the American Society of Clinical Oncology. Unidades: FM, FCF
Subjects: NEOPLASIAS MAMÁRIAS, EMULSÕES (FORMAS FARMACÊUTICAS)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GRAZIANI, Silvia Regina et al. Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemothrapy. Journal of Clinical Oncology. Alexandria: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 23 maio 2024. , 2009
APA
Graziani, S. R., Mendes, S., Vitório, T. S., Padoveze, A. F., Hegg, R., Bydlowski, S. P., & Maranhão, R. C. (2009). Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemothrapy. Journal of Clinical Oncology. Alexandria: Faculdade de Medicina, Universidade de São Paulo.
NLM
Graziani SR, Mendes S, Vitório TS, Padoveze AF, Hegg R, Bydlowski SP, Maranhão RC. Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemothrapy. Journal of Clinical Oncology. 2009 ; 25( 15):[citado 2024 maio 23 ]
Vancouver
Graziani SR, Mendes S, Vitório TS, Padoveze AF, Hegg R, Bydlowski SP, Maranhão RC. Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemothrapy. Journal of Clinical Oncology. 2009 ; 25( 15):[citado 2024 maio 23 ]
Trabalho de evento-resumo periodico
Ki67 tumor expression in breast cancer post-menopausal patient following calcitriol supplementation (2008)
Lyra, E. C.
Source: Journal of Clinical Oncology. Conference titles: Annual Meeting of American Society of Clinical Oncology/ASCO. Unidade: FM
Subjects: REDUÇÃO DO DANO, VITAMINA D (TERAPIA), OSTEOPOROSE (TERAPIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LYRA, E. C. Ki67 tumor expression in breast cancer post-menopausal patient following calcitriol supplementation. Journal of Clinical Oncology. New York: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 23 maio 2024. , 2008
APA
Lyra, E. C. (2008). Ki67 tumor expression in breast cancer post-menopausal patient following calcitriol supplementation. Journal of Clinical Oncology. New York: Faculdade de Medicina, Universidade de São Paulo.
NLM
Lyra EC. Ki67 tumor expression in breast cancer post-menopausal patient following calcitriol supplementation. Journal of Clinical Oncology. 2008 ; 26 1-2.[citado 2024 maio 23 ]
Vancouver
Lyra EC. Ki67 tumor expression in breast cancer post-menopausal patient following calcitriol supplementation. Journal of Clinical Oncology. 2008 ; 26 1-2.[citado 2024 maio 23 ]
Trabalho de evento-resumo periodico
Comparison of tolerability and efficacy of concurrent chemoradiation (CRT) for anal squamous cell carcinoma (SCC) in HIV-positive (HIV+) and -negative (HIV-) patients (pts) (2008)
Souza, C. E.; Castro Jr., G.; Saragiotto, D. F.; Nadalin, W.; Kiss, D. R.; Nahas, C.; Siqueira, S. A.; Hoff, P. M.
Source: Journal of Clinical Oncology. Conference titles: Annual Meeting of the American Society of Clinical Oncology. Unidade: FM
Subjects: CARCINOMA DE CÉLULAS ESCAMOSAS, ANUS (PATOLOGIA), INFECÇÕES POR HIV (PATOLOGIA), HIV (VIROLOGIA), NEOPLASIAS RETAIS, RESUMOS (EVENTOS)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, C. E. et al. Comparison of tolerability and efficacy of concurrent chemoradiation (CRT) for anal squamous cell carcinoma (SCC) in HIV-positive (HIV+) and -negative (HIV-) patients (pts). Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/4606?sid=b63ac5bd-c8dc-4fd6-9860-dbee52d2c586. Acesso em: 23 maio 2024. , 2008
APA
Souza, C. E., Castro Jr., G., Saragiotto, D. F., Nadalin, W., Kiss, D. R., Nahas, C., et al. (2008). Comparison of tolerability and efficacy of concurrent chemoradiation (CRT) for anal squamous cell carcinoma (SCC) in HIV-positive (HIV+) and -negative (HIV-) patients (pts). Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/4606?sid=b63ac5bd-c8dc-4fd6-9860-dbee52d2c586
NLM
Souza CE, Castro Jr. G, Saragiotto DF, Nadalin W, Kiss DR, Nahas C, Siqueira SA, Hoff PM. Comparison of tolerability and efficacy of concurrent chemoradiation (CRT) for anal squamous cell carcinoma (SCC) in HIV-positive (HIV+) and -negative (HIV-) patients (pts) [Internet]. Journal of Clinical Oncology. 2008 ; 26( 15S ): 239s.[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/4606?sid=b63ac5bd-c8dc-4fd6-9860-dbee52d2c586
Vancouver
Souza CE, Castro Jr. G, Saragiotto DF, Nadalin W, Kiss DR, Nahas C, Siqueira SA, Hoff PM. Comparison of tolerability and efficacy of concurrent chemoradiation (CRT) for anal squamous cell carcinoma (SCC) in HIV-positive (HIV+) and -negative (HIV-) patients (pts) [Internet]. Journal of Clinical Oncology. 2008 ; 26( 15S ): 239s.[citado 2024 maio 23 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/4606?sid=b63ac5bd-c8dc-4fd6-9860-dbee52d2c586
Trabalho de evento-resumo periodico
Chemokine receptors seem to impact on patient survival in head and neck squamous cell carcinoma (2006)
Federico, M. H; Campofiorito, C. M; Mangone, F. R; Maistro, S; Pasini, F. S; Bruniatti, K. C; Lehn, C. N; Walter, F; Carvalho, M. B; Brentani, M. M; Snitcovsky, I
Source: Journal of Clinical Oncology. Conference titles: Annual Meeting of the American Society of Clinical Oncology (ASCO). Unidade: FM
Subjects: RECEPTORES, QUIMIOCINAS, CARCINOMA DE CÉLULAS ESCAMOSAS, PACIENTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FEDERICO, M. H et al. Chemokine receptors seem to impact on patient survival in head and neck squamous cell carcinoma. Journal of Clinical Oncology. New York: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 23 maio 2024. , 2006
APA
Federico, M. H., Campofiorito, C. M., Mangone, F. R., Maistro, S., Pasini, F. S., Bruniatti, K. C., et al. (2006). Chemokine receptors seem to impact on patient survival in head and neck squamous cell carcinoma. Journal of Clinical Oncology. New York: Faculdade de Medicina, Universidade de São Paulo.
NLM
Federico MH, Campofiorito CM, Mangone FR, Maistro S, Pasini FS, Bruniatti KC, Lehn CN, Walter F, Carvalho MB, Brentani MM, Snitcovsky I. Chemokine receptors seem to impact on patient survival in head and neck squamous cell carcinoma. Journal of Clinical Oncology. 2006 ; 24( ju 2006):[citado 2024 maio 23 ]
Vancouver
Federico MH, Campofiorito CM, Mangone FR, Maistro S, Pasini FS, Bruniatti KC, Lehn CN, Walter F, Carvalho MB, Brentani MM, Snitcovsky I. Chemokine receptors seem to impact on patient survival in head and neck squamous cell carcinoma. Journal of Clinical Oncology. 2006 ; 24( ju 2006):[citado 2024 maio 23 ]

USP Schools

ReP

Filtros

USP Schools

Departament

Authors

USP affiliated authors

Date published

Subjects

Conference titles

Indexado em

Non normalized affiliation